NCT07503782 is a Phase 2 clinical trial of oleoylethanolamide in Alcohol Use Disorder (AUD), sponsored by Medical University of South Carolina.

Who is sponsoring NCT07503782?

NCT07503782 is sponsored by Medical University of South Carolina.

What drugs are being tested in NCT07503782?

Interventions in NCT07503782: oleoylethanolamide.

What condition does NCT07503782 study?

NCT07503782 studies Alcohol Use Disorder (AUD).

Is NCT07503782 still recruiting?

NCT07503782 is currently not yet recruiting. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT07503782

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

OEA for Young Adults With Alcohol Use Disorder

Not yet recruiting Phase 2 Last updated 31 March 2026

What this trial tests

Phase 2 trial testing oleoylethanolamide in Alcohol Use Disorder (AUD) in 42 participants. Not yet recruiting.

Timeline

1 June 2026

Primary endpoint
31 March 2031

31 March 2031

Quick facts

Lead sponsor	Medical University of South Carolina
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	42
Start date	1 June 2026
Primary completion	31 March 2031
Estimated completion	31 March 2031
Sites	1 location across United States

Drugs / interventions tested

oleoylethanolamide

Conditions studied

Alcohol Use Disorder (AUD) — all drugs for Alcohol Use Disorder (AUD) →

Sponsor

Medical University of South Carolina

Who can join

Adults 18 to 25, any sex, with Alcohol Use Disorder (AUD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate the effects of oleoylethanolamide (OEA) supplementation on inflammation, the oral microbiome, neurocognitive function, and alcohol use in young adults ages 18 to 25 with alcohol use disorder (AUD). The main questions it aims to answer are: * Does OEA reduce peripheral markers of immune activation (IL-6, TNF-α, IL-1β, and LPS)? * Does OEA alter oral microbiome composition? * Does OEA improve neurocognitive measures of reward sensitivity and impulsivity? Researchers will compare OEA to a placebo (a look-alike substance with no active ingredient) to determine whether OEA improves biological and behavioral outcomes associated with AUD. Participants (N = 42) will: * Be randomly assigned to receive 300mg TRIPTI (providing 250 mg/day of OEA) or placebo for 6 weeks. * Provide blood, saliva, and urine samples * Complete cognitive testing and questionnaires * Report alcohol use during the study * Attend in-person study visits for monitoring and assessments This randomized, double-blind, placebo-controlled pilot trial will provide preliminary data on the potential efficacy of OEA as a multi-system intervention for young adults with AUD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Alcohol Use Disorder (AUD)

Currently open trials in the same condition.

NCT07118618 — Probenecid Administration for Alcohol Craving and Consumption · Phase 2 · recruiting
NCT07040592 — Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide · Phase 2 · recruiting
NCT06949423 — Assessing the Impact of dTMS on Neural Targets Associated With Alcohol Use Disorder · NA · recruiting
NCT06070649 — The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) · Phase 1 · recruiting
NCT06335407 — Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study · Phase 1 · recruiting

Other Medical University of South Carolina trials

Trials by the same sponsor.

NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07503782 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07503782.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing